TQ B3101Alternative Names: TQ-B3101
Latest Information Update: 20 Jan 2017
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 10 Jan 2017 Preclinical trials in Solid tumours in China (PO)
- 10 Jan 2017 Jiangsu Chia-tai Tianqing Pharmaceutical plans a phase I trial in Solid tumours (Late-stage disease) in China (NCT03019276)